| TOP STORY | New Method for Producing Heart Cells May Hold the Key to Treating Heart Failure Scientists discovered how to make a new type of cell that is in between embryonic stem cells and adult heart cells, and that may hold the key to treating heart disease. These induced expandable cardiovascular progenitor cells can organically develop into heart cells, while still being able to replicate. When injected into a mouse after a heart attack, the cells improved heart function dramatically. [Press release from the Gladstone Institutes discussing online prepublication in Cell Stem Cell] Press Release | Full Article | Graphical Abstract | |
| SCIENCE NEWS | Compugen Presents Results for CGEN-15029 Immuno-Oncology Therapeutic Program Compugen USA, Inc. presented results for CGEN-15029, the lead internal program in the company’s immuno-oncology therapeutics pipeline. [Press release from Compugen USA, Inc. discussing research presented at Emerging Approaches to Cancer Immunotherapy, New York] Press Release Top-Line Data from All Patients on the Primary Endpoint of Kiadis Pharma’s Phase II Trial with ATIR101™ Selected for Oral Presentation Kiadis Pharma N.V. announced that key data from the company’s ongoing single-dose Phase II clinical trial with its lead product ATIR101™ has been selected for an oral presentation to discuss the top-line data. [Press release from the Kiadis Pharma N.V. discussing research to be presented at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Valencia] Press Release bluebird bio to Present Clinical Data on Lenti-D in CALD in Plenary Session bluebird bio, Inc. announced that interim data from the ongoing Phase II/III Starbeam Study for the treatment of cerebral adrenoleukodystrophy (CALD) will be presented in an oral presentation. [Press release from the bluebird bio, Inc. discussing research to be presented at the American Academy of Neurology (AAN) 2016 Annual Meeting, Vancouver] Press Release Advaxis Study in Head and Neck Cancer Selected for Late-Breaking Poster Advaxis, Inc. announced that data from a Phase II study of its lead Lm immunotherapy candidate in HPV-associated head and neck cancer, axalimogene filolisbac (AXAL), has been selected as a late-breaker poster presentation. [Press release from Advaxis, Inc. discussing research to be presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, New Orleans] Press Release Omalizumab Decreases Colds in Inner-City Children with Asthma, NIH Study Reports Treatment with omalizumab significantly decreases the number of colds in inner-city children with allergic asthma, researchers reported at a press conference. [Press release from National Institute of Allergy and Infectious Diseases discussing research presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2016 Annual Meeting, Los Angeles] Press Release |
| BUSINESS | CEL-SCI Reports Monthly Patient Enrollment in February for Its Phase III Head and Neck Cancer Trial CEL-SCI Corporation announced that during the month of February it has enrolled 27 patients in its ongoing Phase III trial of its investigational immunotherapy Multikine in patients with advanced primary head and neck cancer. [CEL-SCI Corporation] Press Release Baxalta Commences Phase I Clinical Trial of BAX 826, the Company’s Second Extended Half-Life Factor VIII Treatment for Hemophilia A Baxalta Incorporated announced that it has dosed the first patient in its Phase I, first-in-human clinical trial of BAX 826, a recombinant Factor VIII treatment for hemophilia A that uses proprietary polysialic acid technology to extend its circulating half-life. [Baxalta Incorporated] Press Release miRagen Therapeutics Initiates First Clinical Trial for MRG-106 in Lymphoma Patients miRagen Therapeutics, Inc. announced that it has initiated a Phase I clinical study of its anti-cancer product candidate MRG-106, a synthetic microRNA antagonist of microRNA-155. [miRagen Therapeutics, Inc.] Press Release Celyad Receives the First US Patent Covering a Method of Producing Allogeneic TCR-Deficient CAR T-Cells Celyad announced the issuance of United States Patent No. 9,273,283 relating to a method of producing allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and express a chimeric antigen receptor (CAR). [Celyad] Press Release Merck, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer Merck, Pfizer and Verastem announced that they have entered into an agreement to evaluate avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem’s VS-6063, an investigational focal adhesion kinase inhibitor, in patients with advanced ovarian cancer. [Verastem, Inc.] Press Release SELLAS Life Sciences Announces FDA Orphan Drug Designation for WT1 Cancer Vaccine in Patients with Malignant Pleural Mesothelioma SELLAS Life Sciences Group announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for the company’s WT1 cancer vaccine for the treatment of patients with malignant pleural mesothelioma. [SELLAS Inc.] Press Release Wills Eye Hospital Treats 1st U.S. Patient in New Gene Therapy RESCUE Trial Wills Eye Hospital announced it has treated the first RESCUE trial patient in the United States enrolled in an FDA-approved gene therapy vision research study. [Wills Eye Hospital (PR Newswire Association LLC)] Press Release Cancer MoonShot 2020 Community Oncology Milestone: National Immunotherapy Coalition (NIC) Partners with New England Cancer Specialists to Advance Cancer Care in New England Cancer MoonShot 2020 announced its clinical affiliation with New England Cancer Specialists (NECS), aimed to greatly expand patients’ access to advanced cancer care, innovative clinical trials, and survivorship resources in the community. [Cancer MoonShot 2020] Press Release FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (Pembrolizumab) in Advanced Non-Small Cell Lung Cancer Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review a new sBLA for KEYTRUDA®, the company’s anti-PD-1 therapy, to include data from KEYNOTE-010. [Merck Sharp & Dohme Corp.] Press Release |
|